The Korean Journal of Urological Oncology 2014;12(3):124-131.
Published online December 30, 2014.
Predictive Factors for Maximal Size Reduction of Renal Target Lesion in Patients with Metastatic Renal Cell Carcinoma Receiving Targeted Therapies
Sung Han Kim 1, In-Chang Cho 2, Sun Ho Kim 3, Jae Young Joung 1, Ho Kyung Seo 1, Kang Hyun Lee 1, Heong Dong Yuk 4, Jinsoo Chung 1
021Department of Urology, Department of Urology, National Police Hospital, Seoul, Korea
31Department of Urology, Department of Radiology, Center for Prostate Cancer, National Cancer Center, Goyang, Korea
41Department of Urology, Department of Urology, Seoul National University Hospital, Seoul, Korea
Correspondence:  Jinsoo Chung
Abstract
treated with targeted therapy (TT) and to determine predictive factors for maximal tumor size reduction. Materials and Methods: We reviewed the clinical and radiographic data of 43 mRCC patients with 47 primary renal target legions (RTL) treated with at least two cycles of TT between 2007 and 2011. RTL response was evaluated using Response Evaluation Criteria Solid Tumors (RECIST) v.1.1. The significant predictive factors corresponding to the best response of RTL size reduction between the size reduction group (RG, n=36) and the non-reduction group (NRG, n=11) was statistically analyzed. Results: During a median follow-up period of 7.4 months, median RTL size was 82mm and its mean change in size was -7.35mm. Multivariate analysis showed that body surface area (BSA) (p=0.016) and RTL size (p=0.024) were independently significant in shorter time to maximize size reduction. After classification of four RTL groups according to the combination of BSA of 1.62m2 and RTL size of 82mm, significant differences in time to maximal size reduction were observed (log rank, p=0.009). Conclusions: BSA and RTL size were the best predictive factors for reduction of RTL size with time for maximal tumor response during TT. (Korean J Urol Oncol 2014;12:124-131)
Key Words: Renal cell carcinoma, Targeted therapy, Response, Size


Editorial Office
Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine,
101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
TEL: +82-2-2072-0817,   FAX: +82-2-742-4665   Email: journal@e-juo.org                

Copyright © The Korean Urological Oncology Society.

Developed in M2PI